Compare Cytokinetics Inc (CYTK) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs VICI Properties Inc — how do they compare? Cytokinetics Inc trades at $76.67 (market cap $10.78B), while VICI Properties Inc trades at $26.03 (market cap $28.71B). The key difference: VICI Properties Inc is far larger — about 2.7× Cytokinetics Inc's market cap, and VICI Properties Inc pays a 6.9% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | VICI | |
|---|---|---|
Market Cap | $10.78B | $28.71B |
Sector | Technology | Real Estate |
52-Week High | $87.26 | $33.78 |
52-Week Low | $34.31 | $25.94 |
Enterprise Value | $10.88B | $46.26B |
Dividend Yield | — | 6.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $76.76, down 5.67% today, with a bearish technical signal and negative profitability metrics. Recent Q2 2026 earnings beat EPS estimates but missed on revenue, while the company's drug Myqorzo shows strong commercial uptake and regulatory approvals in the UK. Cash flow remains negative from operations, offset by financing activities.
The outlook is mixed: strong analyst buy ratings (97%) and a $111.14 price target suggest upside, but high cash burn, competitive pressures, and lack of profitability pose significant risks. Investment appeal hinges on successful drug commercialization and path to profitability.
VICI Properties trades at $26.74, up 0.66% today, with a neutral technical signal and strong fundamentals including a 67.5% net income margin and a P/E of 10.1. Recent Q2 2026 earnings showed an EPS miss but revenue beat, while the company raised its full-year AFFO guidance. A $1.75 billion note offering in August 2026 supports capital deployment.
The outlook remains positive with a 76.9% analyst buy rating and a $29.83 consensus price target, offering potential upside. Risks include earnings volatility and high debt, but the near 7% dividend yield and stable cash flows provide investor appeal in the REIT sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
